Cambridge Cognition Awarded FDA Marketing Clearance for Cantab Mobile

January 25, 2017

Neuroscience digital health company, Cambridge Cognition has achieved FDA marketing clearance for its Cantab mobile.

The device is designed to detect clinically-relevant memory impairment in older adults at the point of care. It includes a computerized test of visuospatial associative learning (CANTAB PAL) to assess episodic memory with optional mood and functional assessments.

The touchscreen test takes less than 10 minutes to complete. — Cynthia Jessup

View today's stories